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Editorial: The Role of Radiotherapy in Acromegaly
The manuscript of Barkan et al. (1), in this issue of JCEM
(see page 3187), in which they describe the inefficacy of
pituitary irradiation in normalizing serum insulin-like
growth factor I (IGF-I) concentrations in patients with acro-
megaly, is interesting because it is the first report that uses
IGF-I instead of GH as the parameter for the efficacy of
radiotherapy in acromegaly. Most previous reports use GH
as the parameter in the long-term follow-up of acromegalic
patients after radiotherapy (2–4). Roughly, these studies in-
dicate that, after two yr, GH concentrations decrease by
about 50% from baseline levels, and by five yr the GH con-
centrations are about 25% of the initial values. Speirs et al. (5)
reported that radiotherapy is equally efficacious whether an
earlier unsuccessful ablative procedure had been used or not.
Acromegalic patients frequently do have abnormally large
frontal air sinuses, which allow increased anterior beam
transmission. This can cause an increased dose to the optic
nerve and chiasm with potentially damaging effects. The
resultant overdosage can be greater than 5% of the intended
dose (6). These authors recommended therefore that acro-
megalic patients should be treated with a more acurately
directed beam, which avoids the air sinuses altogether. De-
spite this, radiotherapy for acromegaly is a safe procedure in
the long-term, with few reports of damage to the optic nerves
(7, 8). The incidence of second brain tumors after pituitary
irradiation is also low (9). Little is known, however, about the
long-term effect of irradiation of the pituitary area on neuro-
psychological functions (9–11). The relationship between
GH and IGF-I levels in patients with acromegaly does not
follow a straight line. Only in GH concentrations up to 40–60
mg/L do GH and IGF-I demonstrate a close correlation, but
higher GH concentrations do not lead to a further increase in
IGF-I levels in most patients (12, 13). However, many patients
demonstrate increased serum IGF-I levels in the follow-up,
while GH concentrations are within the normal range and
vice versa (13). After the introduction of somatostatin ana-
logs in the treatment of acromegaly, the need for radiother-
apy has decreased. The somatostatin analogs available (oc-
treotide and lanreotide) decrease GH and IGF-I levels to
normal levels in about 60% of patients (14). The recently
developed long-acting somatostatin analogs will simplify
therapy for these patients and will encourage their compli-
ance, while the effectiveness of normalizing GH and IGF-I
levels might be higher (15–20). With better medical treatment
available, fewer acromegalic patients who fail surgical ther-
apy will need radiotherapy. This is especially true for elderly
patients, who are more sensitive to somatostatin analog ther-
apy (13). One of the shortcomings of the study by Barkan and
coworkers (1), as they themselves pointed out, is that no
uniform radiotherapy technique was used in this retrospec-
tive study. Both proton beam radiotherapy and conventional
radiation techniques were used, and patients were treated in
several centers. The relatively low number of subjects in this
study and the variability of the IGF-I assays used make it
hard to draw final conclusions. In our own database, we
looked for the course of serum IGF-I concentrations in ac-
romegalic patients. In a group of 37 patients who were not
cured after transsphenoidal surgery and radiotherapy and
who could be followed for a period of 7 yr, we found that
IGF-I concentrations had not normalized, even after a fol-
low-up period of 7 yr. In the same group, anterior pituitary
insufficiency had developed in about 40% (39% thyroidal
insufficiency; 33% gonadal insufficiency; 42% adrenal insuf-
ficiency). This clearly demonstrates that pituitary damage
frequently occurs after radiotherapy. The lowering of GH
levels further supports the damaging effect of radiotherapy
on the pituitary fossa. Why then do serum IGF-I concentra-
tions not normalize, and what does this mean from a clinical
viewpoint?
One of the major problems in assessing disease activity in
acromegaly is the fact that neither serum GH nor IGF-I con-
centrations have been shown to be reliable parameters, al-
though recently some investigators suggested a possible role
for IGFBP-3 (21–24). There is consensus, however, that in
patients with normal serum GH and IGF-I concentrations,
disease activity is absent or low. It remains uncertain
whether one or several GH samples or 24 hr GH profiles are
necessary to obtain an impression of GH secretory reserve
(21, 23). Why did serum IGF-I levels demonstrate such a
disappointing decrease after radiotherapy?
One might speculate on a role of IGF-I modulating tissue
repair after irradiation or ischemia. In acromegalics IGF-I
levels are increased, which in theory might influence the
outcome of radiotherapy. Several reports demonstrated that
IGF-I can decrease cellular damage in cases of ischemia (25–
27). IGF-I might be a potent neuronal rescue agent when
injury is imminent in case of ischemia. When tissue damage
is caused by irradiation, however, the role of IGF-I could be
less beneficial (28). By inducing changes in chromatin con-
firmation IGF-I inhibits repair of irradiation-damaged DNA.
Whether this plays a role where radiotherapy in acromegaly
is concerned is not known. It would not explain why tu-
morous GH levels decrease after radiotherapy in these pa-
tients, while IGF-I concentrations do so to a much lesser
extent. If these findings by Barkan and coworkers turn out to
be correct, while we do not know the long-term adverse effect
of radiotherapy on neuropsychiatric functions, we probably
should reserve irradiation of the pituitary tumor (remnants)
in acromegalic patients with active disease to those in whom
other treatments like somatostatin analogs have failed to
control disease activity.
However, more studies should be carried out to find the
optimal biochemical parameters to be used in defining a
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“cure” of acromegaly. Also the high costs of long-term so-
matostatin analog therapy should be considered. In the
meantime we reserve radiotherapy only for acromegalics
with large, infiltrating pituitary tumors that cannot be cured
surgically and that are also not controlled by somatostatin
analog treatment with repeated long-acting depot prepara-
tions. This means that fewer patients will receive radiother-
apy in future. Up till now, in many centers, including ours,
patients who are not cured after neurosurgery are still treated
with radiotherapy. With the report by Barkan et al. (1), how-
ever, the discussion about the role of radiotherapy is again
intensified.
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